Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing new therapies for metabolic and endocrine disorders. The company is headquartered in San Diego, California. Show more

9920 PACIFIC HEIGHTS BOULEVARD, SAN DIEGO, CA, UNITED STATES, 92121, San Diego, CA, 92121, USA

https://www.vikingtherapeutics.com

BIOTECHNOLOGY

HEALTHCARE

Start AI Chat

Market Cap

3.953B

52 Wk Range

$22.96 - $43.15

Previous Close

$34.36

Open

$34.79

Volume

1,502,760

Day Range

$33.47 - $34.98

Enterprise Value

3.456B

Cash

125.8M

Avg Qtr Burn

-125.2M

Insider Ownership

3.10%

Institutional Own.

66.12%

Qtr Updated

06/30/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
VK2735 (Injectable) Details Metabolic disorder, Obesity	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VK2735 (Oral formulation) Details Obesity	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VK2809 Details Non-alcoholic steatohepatitis	Phase 2b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VK0214 Details X-linked adrenoleukodystrophy	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VK3019 (Amylin Agonist) Details Obesity	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VK5211 (SARM) Details Muscle injury following hip fracture	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.